

(FILE 'HOME' ENTERED AT 21:55:47 ON 07 DEC 2006)

FILE 'USPATFULL' ENTERED AT 21:57:08 ON 07 DEC 2006

FILE 'USPATFULL, USPAT2, CAPLUS' ENTERED AT 21:57:24 ON 07 DEC 2006  
ACTIVATE L10709121/L

-----  
L1 ( 3746)SEA FILE=USPATFULL ABB=ON PLU=ON PHOTODYNAMIC  
L2 ( 463)SEA FILE=USPAT2 ABB=ON PLU=ON PHOTODYNAMIC  
L3 ( 13999)SEA FILE=CAPLUS ABB=ON PLU=ON PHOTODYNAMIC  
L4 ( 18208)SEA PHOTODYNAMIC  
L5 ( 3133)SEA FILE=USPATFULL ABB=ON PLU=ON (((PHOTODYNAMIC) OR (PHOTO (1W)  
L6 ( 402)SEA FILE=USPAT2 ABB=ON PLU=ON (((PHOTODYNAMIC) OR (PHOTO (1W)  
L7 ( 7668)SEA FILE=CAPLUS ABB=ON PLU=ON (((PHOTODYNAMIC) OR (PHOTO (1W)  
L8 ( 11203)SEA (((PHOTODYNAMIC) OR (PHOTO (1W) DYNAMIC) OR ("PHOTO-DYNAMIC  
L9 ( 8)SEA FILE=USPATFULL ABB=ON PLU=ON (PROTECT? OR PREVENT? OR RED  
L10 ( 0)SEA FILE=USPAT2 ABB=ON PLU=ON (PROTECT? OR PREVENT? OR REDUCI  
L11 ( 0)SEA FILE=CAPLUS ABB=ON PLU=ON (PROTECT? OR PREVENT? OR REDUCI  
L12 ( 8)SEA (PROTECT? OR PREVENT? OR REDUCING? OR DECREASE? OR REDUCTIO  
L13 ( 236468)SEA FILE=USPATFULL ABB=ON PLU=ON (PROTECT? OR PREVENT? OR RED  
L14 ( 27220)SEA FILE=USPAT2 ABB=ON PLU=ON (PROTECT? OR PREVENT? OR REDUCI  
L15 ( 140962)SEA FILE=CAPLUS ABB=ON PLU=ON (PROTECT? OR PREVENT? OR REDUCI  
L16 ( 404650)SEA (PROTECT? OR PREVENT? OR REDUCING? OR DECREASE? OR REDUCTIO  
L17 ( 136547)SEA FILE=USPATFULL ABB=ON PLU=ON (SORROUND? OR ADJACENT? ) (1  
L18 ( 18917)SEA FILE=USPAT2 ABB=ON PLU=ON (SORROUND? OR ADJACENT? ) (1S)  
L19 ( 24421)SEA FILE=CAPLUS ABB=ON PLU=ON (SORROUND? OR ADJACENT? ) (1S)  
L20 ( 179885)SEA (SORROUND? OR ADJACENT? ) (1S) (TISSUE OR CELL? OR (NONTARG  
L21 ( 17578)SEA FILE=USPATFULL ABB=ON PLU=ON L13 AND L17  
L22 ( 1983)SEA FILE=USPAT2 ABB=ON PLU=ON L14 AND L18  
L23 ( 133)SEA FILE=CAPLUS ABB=ON PLU=ON L15 AND L19  
L24 ( 19694)SEA L16 AND L20  
L25 ( 454)SEA FILE=USPATFULL ABB=ON PLU=ON L21 AND L5  
L26 ( 50)SEA FILE=USPAT2 ABB=ON PLU=ON L22 AND L6  
L27 ( 0)SEA FILE=CAPLUS ABB=ON PLU=ON L23 AND L7  
L28 ( 504)SEA L24 AND L8  
L29 ( 179592)SEA FILE=USPATFULL ABB=ON PLU=ON (SORROUND? OR ADJACENT? OR H  
L30 ( 24114)SEA FILE=USPAT2 ABB=ON PLU=ON (SORROUND? OR ADJACENT? OR HEAL  
L31 ( 65010)SEA FILE=CAPLUS ABB=ON PLU=ON (SORROUND? OR ADJACENT? OR HEAL  
L32 ( 268716)SEA (SORROUND? OR ADJACENT? OR HEALTH? ) (1S) (TISSUE OR CELL?  
L33 ( 33118)SEA FILE=USPATFULL ABB=ON PLU=ON L13 AND L29  
L34 ( 3856)SEA FILE=USPAT2 ABB=ON PLU=ON L14 AND L30  
L35 ( 914)SEA FILE=CAPLUS ABB=ON PLU=ON L15 AND L31  
L36 ( 37888)SEA L16 AND L32  
L37 ( 791)SEA FILE=USPATFULL ABB=ON PLU=ON L33 AND L5  
L38 ( 92)SEA FILE=USPAT2 ABB=ON PLU=ON L34 AND L6  
L39 ( 3)SEA FILE=CAPLUS ABB=ON PLU=ON L35 AND L7  
L40 ( 886)SEA L36 AND L8  
L41 ( 2687)SEA FILE=USPATFULL ABB=ON PLU=ON L13 (1S) L29  
L42 ( 326)SEA FILE=USPAT2 ABB=ON PLU=ON L14 (1S) L30  
L43 ( 394)SEA FILE=CAPLUS ABB=ON PLU=ON L15 (1S) L31  
L44 ( 3407)SEA L16 (1S) L32  
L45 ( 15)SEA FILE=USPATFULL ABB=ON PLU=ON L41 (2S) L5  
L46 ( 5)SEA FILE=USPAT2 ABB=ON PLU=ON L42 (2S) L6  
L47 ( 1)SEA FILE=CAPLUS ABB=ON PLU=ON L43 (2S) L7  
L48 ( 21)SEA L44 (2S) L8  
L49 ( 2)SEA FILE=USPATFULL ABB=ON PLU=ON L13 AND VACCUM (30A) L29 AND  
L50 ( 1)SEA FILE=USPAT2 ABB=ON PLU=ON L14 AND VACCUM (30A) L30 AND L6  
L51 ( 0)SEA FILE=CAPLUS ABB=ON PLU=ON L15 AND VACCUM (30A) L31 AND L7  
L52 ( 3)SEA L16 AND VACCUM (30A) L32 AND L8  
L53 ( 297)SEA FILE=USPATFULL ABB=ON PLU=ON L13 AND VACUUM (30A) L29 AND  
L54 ( 39)SEA FILE=USPAT2 ABB=ON PLU=ON L14 AND VACUUM (30A) L30 AND L6  
L55 ( 0)SEA FILE=CAPLUS ABB=ON PLU=ON L15 AND VACUUM (30A) L31 AND L7  
L56 ( 336)SEA L16 AND VACUUM (30A) L32 AND L8  
L57 ( 644)SEA FILE=USPATFULL ABB=ON PLU=ON L13 AND (OXYGEN OR VACUUM) (

```

L58 (      77)SEA FILE=USPAT2 ABB=ON  PLU=ON  L14 AND (OXYGEN OR VACUUM) (30A
L59 (      0)SEA FILE=CAPLUS ABB=ON  PLU=ON  L15 AND (OXYGEN OR VACUUM) (30A
L60 (     721)SEA L16 AND (OXYGEN OR VACUUM) (30A) L32 AND L8
L61 (      6)SEA FILE=USPATFULL ABB=ON  PLU=ON  L13 AND (OXYGEN (30A)VACUUM)
L62 (      0)SEA FILE=USPAT2 ABB=ON  PLU=ON  L14 AND (OXYGEN (30A)VACUUM) (3
L63 (      0)SEA FILE=CAPLUS ABB=ON  PLU=ON  L15 AND (OXYGEN (30A)VACUUM) (3
L64 (      6)SEA L16 AND (OXYGEN (30A) VACUUM) (30A) L32 AND L8
-----
L65      12779 FILE USPATFULL
L66      1542 FILE USPAT2
L67      4507 FILE CAPLUS
TOTAL FOR ALL FILES
L68      18828 S NON-TARGET? OR (NON TARGET?) OR NONTARGET?
L69      3133 FILE USPATFULL
L70      402 FILE USPAT2
L71      7668 FILE CAPLUS
TOTAL FOR ALL FILES
L72      11203 S L8
L73      658 FILE USPATFULL
L74      99 FILE USPAT2
L75      3068 FILE CAPLUS
TOTAL FOR ALL FILES
L76      3825 S PHOTOTOXICIT?
L77      3133 FILE USPATFULL
L78      402 FILE USPAT2
L79      7668 FILE CAPLUS
TOTAL FOR ALL FILES
L80      11203 S L8
L81      15730 FILE USPATFULL
L82      1891 FILE USPAT2
L83      5040 FILE CAPLUS
TOTAL FOR ALL FILES
L84      22661 S L68 OR ( HELATHY TISSUE? OR HEALTHY CELL?)
L85      436 FILE USPATFULL
L86      58 FILE USPAT2
L87      27 FILE CAPLUS
TOTAL FOR ALL FILES
L88      521 S L84 AND L80
L89      141 FILE USPATFULL
L90      24 FILE USPAT2
L91      13 FILE CAPLUS
TOTAL FOR ALL FILES
L92      178 S L84 (50A) (OXYGEN OR HYPOXI?)
L93      458 FILE USPATFULL
L94      64 FILE USPAT2
L95      763 FILE CAPLUS
TOTAL FOR ALL FILES
L96      1285 S L8 (50A) (L16 OR INHIBIT?)
L97      2590 FILE USPATFULL
L98      343 FILE USPAT2
L99      1084 FILE CAPLUS
TOTAL FOR ALL FILES
L100     4017 S (L72 OR L84) (50A) (L16 OR INHIBIT?)
L101      81 FILE USPATFULL
L102      11 FILE USPAT2
L103      18 FILE CAPLUS
TOTAL FOR ALL FILES
L104     110 S L100 (50A) (OXYGEN OR HYPOXI?)
          SAVE ALL TEMP L10709121/L

```

epithelial tissue during PDT in which **phototoxicity** of the photosensitizing agent is inhibited in **non-targeted epithelial tissue** during the application of light to a targeted treatment site.

DETD . . . are used with ALA-induced PDT, which is described in more detail in U.S. Patent Publication No. 2002/0099094A1 entitled "Topical Aminolevulinic Acid-**Photodynamic Therapy** For The Treatment Of Acne Vulgaris." As disclosed therein, ALA can be used in a variety of forms, including in a pharmacologically equivalent.

DETD . . . portion of the tissue from the external environment. A chamber 12 within the device 10 can be coupled to a **vacuum** 14 to **decrease** local circulation and delivery of oxygenated blood, and/or the chamber 12 can be flushed with nitrogen to deprive the tissue surface of **oxygen**, thereby **preventing phototoxicity** to the epidermal tissue surface. The device 10 is preferably used simultaneously with the application of light, and thus at.

DETD . . . suction and blood flow near the tissue surface is reduced and the tissue is deprived of oxygen. Light exposure for **photodynamic therapy** is then administered. The photosensitizing agent located in the epidermal tissue is thereby prevented from becoming phototoxic when the tissue. . .

DETD . . . targeted treatment site, as described in a U.S. patent application filed concurrently herewith and titled "Methods for Epidermal Protection During **Photodynamic Therapy**."

DETD . . . the method is used during hair removal to establish an oxygen gradient with relative hypoxia in the interfollicular epidermis to **decrease** the phototoxic effects of PDT in this skin layer relative to the deeper-seated hair follicles, where **phototoxicity** is desired. This would allow for the enhanced efficiency of hair removal while minimizing side effects secondary to epidermal damage. . .

DETD . . . tourniquet applied to the extremity for 1 minute prior to and during irradiation, (c) a control, and (d) an external **vacuum** applied to skin. As shown in FIG. 2A, the decreased **oxygen** in the skin (b) caused by the tourniquet was effective to remove hair, as compared to the control (a), and as shown in FIG. 2B, the decreased **oxygen** in the skin (d) caused by the external **vacuum** was effective to remove hair, as compared to the control (c).

CLM What is claimed is:

1. A method for protecting non-targeted tissue during **photodynamic therapy** induced using a photosensitizing agent or a pre-photosensitizing agent, the method comprising the steps of: administering an agent to a. . .

2. The method of claim 1, wherein the step of inhibiting **phototoxicity** of the photosensitizing agent in non-targeted tissue comprises **reducing** the oxygen-content in the non-targeted tissue during the step of irradiating the treatment site.

3. The method of claim 2, wherein the step of reducing the **oxygen**-content in the non-targeted tissue comprises applying an external **vacuum** to the non-targeted tissue.

15. A device for protecting non-targeted tissue during **photodynamic therapy** induced using a photosensitizing agent or a pre-photosensitizing agent, comprising: a tissue-contacting member adapted to decrease local circulation and delivery. . . a portion of the tissue-contacting member being transparent to allow light from an irradiating light source to pass therethrough during **photodynamic therapy**.

ACCESSION NUMBER:

2004:328029 USPATFULL

TITLE:

METHODS AND DEVICES FOR EPITHELIAL PROTECTION DURING

INVENTOR(S): **PHOTODYNAMIC THERAPY**  
 Anderson, Richard Rox, 339 Marrett Road, Lexington, MA,  
 UNITED STATES 02421  
 Ortel, Bernhard, 10 Emerson Place, 14C, Boston, MA,  
 UNITED STATES 02114  
 Battle, Eliot F., 5300 43rd St. NW, Washington, DC,  
 UNITED STATES 20015  
 Joe, Edwin K., 520 West 23rd Street, New York, NY,  
 UNITED STATES 10011  
 PATENT ASSIGNEE(S): MASSACHUSETTS GENERAL HOSPITAL, Charlestown, MA (U.S.  
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004259854	A1	20041223
APPLICATION INFO.:	US 2004-709121	A1	20040414 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-462937P	20030415 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02210-2604	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	316	

L104 ANSWER 65 OF 110 USPATFULL on STN

DETD . . . essentially immediately with the exposure of the recipient to an ambient light source of a wavelength appropriate for producing activated oxygen with a substantially reduced risk of non-target toxicity.

ACCESSION NUMBER: 1999:136685 USPATFULL

TITLE: Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore

INVENTOR(S): Fritzberg, Alan R., Edmonds, WA, United States  
Abrams, Paul G., Seattle, WA, United States  
Reno, John M., Brier, WA, United States  
Axworthy, Donald B., Brier, WA, United States  
Graves, Scott S., Monroe, WA, United States  
Kasina, Sudhakar, Kirkland, WA, United States

PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5976535		19991102
APPLICATION INFO.:	US 1995-468513		19950606 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-163188, filed on 7 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. WO 1993-US5406, filed on 7 Jun 1993 which is a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5288342		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Cunningham, Thomas M.		
LEGAL REPRESENTATIVE:	Seed and Berry LLP		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 13 Drawing Page(s)		
LINE COUNT:	4278		

L104 ANSWER 57 OF 110 USPATFULL on STN

SUMM . . . proteins like calmodulin. These treatments, however, are not restricted to the damaged cells. They can affect the function of normal, healthy cells and cause a number of adverse side effects. More selective methods are, therefore, needed to treat or prevent calcium mediated damage in cells deprived of oxygen, while avoiding these adverse side effects.

ACCESSION NUMBER: 2001:171156 USPATFULL  
TITLE: Method and composition for treating and preventing pathogenic effects caused by intracellular calcium overload  
INVENTOR(S): Pearlstein, Robert D., Durham, NC, United States  
Kramer, Richard S., Millbrae, CA, United States  
PATENT ASSIGNEE(S): Leigh Biotechnology, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001027206	A1	20011004
	US 6380254	B2	20020430
APPLICATION INFO.:	US 2001-804640	A1	20010312 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-410062, filed on 1 Oct 1999, ABANDONED Continuation of Ser. No. US 1997-939906, filed on 29 Sep 1997, ABANDONED Continuation of Ser. No. US 1995-516181, filed on 17 Aug 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-188411, filed on 24 Jan 1994, ABANDONED		
DOCUMENT TYPE:	Utility		

L104 ANSWER 110 OF 110 CAPLUS COPYRIGHT 2006 ACS on STN

AB . . . Ar-driven dye laser) alone or in combination with the hypoxic cell radiosensitizer, misonidazole (MISO). In vitro studies had suggested that hypoxia might decrease the cytotoxicity of photodynamic therapy (PDT) and labeling with [14C]MISO had revealed a significant fraction of viable hypoxic cells in this tumor. PDT alone resulted in a growth delay of 8.8 days but no tumor cures were observed.

ACCESSION NUMBER: 1986:438348 CAPLUS

DOCUMENT NUMBER: 105:38348

TITLE: Treatment of Dunning R3327-AT rat prostate tumors with photodynamic therapy in combination with misonidazole  
AUTHOR(S): Gonzalez, Salomon; Arnfield, Mark R.; Meeker, Bert E.; Tulip, John; Lakey, William H.; Chapman, J. Donald; McPhee, Malcolm S.

CORPORATE SOURCE: Dep. Surg., Univ. Alberta, Edmonton, AB, T6G 2E1, Can.

SOURCE: Cancer Research (1986), 46(6), 2858-62

CODEN: CNREA8; ISSN: 0008-5472

DOCUMENT TYPE: Journal

LANGUAGE: English

=>

L104 ANSWER 104 OF 110 CAPLUS COPYRIGHT 2006 ACS on STN

IT Mammary gland

(carcinoma, inhibitors, photosensitizing; oxygen  
effect in photodynamic therapy with Photofrin and  
laser radiation)

ACCESSION NUMBER: 1997:415867 CAPLUS

DOCUMENT NUMBER: 127:47205

TITLE: Oxygen effect of photodynamic therapy

AUTHOR(S): Chen, Qun; Chen, Hua; Murphy, Juli B.; Shapiro,  
Howard; Hetzel, Fred W.

CORPORATE SOURCE: Research and Development, HealthONE, Denver, CO,  
80218, USA

SOURCE: Proceedings of SPIE-The International Society for  
Optical Engineering (1997), 2972 (Optical Methods for  
Tumor Treatment and Detection: Mechanisms and  
Techniques in Photodynamic Therapy VI), 80-87  
CODEN: PSISDG; ISSN: 0277-786X

PUBLISHER: SPIE-The International Society for Optical Engineering  
DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L104 ANSWER 99 OF 110 CAPLUS COPYRIGHT 2006 ACS on STN

AB **Photodynamic tumor therapy** (PDT) on the basis of a sequential two-photon excitation of suitable sensitizers is expected 1) to **prevent skin phototoxicity** caused by day-light and 2) may occur via an **oxygen**-independent mechanism of photosensitization. Here we investigated cellular uptake, localization and phototoxicity of (t-butyl)4-PcMg, a promising dye for a sequential two-step.

ACCESSION NUMBER: 2003:10752 CAPLUS

DOCUMENT NUMBER: 138:299880

TITLE: Alkyl-substituted magnesium phthalocyanine: phototoxicity after excitation of higher electronic states in cells in vitro

AUTHOR(S): Paul, Andrea; Molich, Andreas; Oelckers, Stefan; Seifert, Martina; Roder, Beate

CORPORATE SOURCE: Department of Physics., Humboldt University of Berlin, Berlin, 11115, Germany

SOURCE: Journal of Porphyrins and Phthalocyanines (2002), 6(5), 340-346

CODEN: JPPHFZ; ISSN: 1088-4246

PUBLISHER: Society of Porphyrins & Phthalocyanines

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE

L48 ANSWER 14 OF 21 USPATFULL on STN

DETD . . . . same numerical designation as the elements in FIGS. 2 and 3. It will be generally understood that patch 20A applies **photodynamic therapy** to dermal lesions 10, FIG. 5, in substantially the same manner as patch 20 of FIGS. 2 and 3. However, . . . as the underlying dermal lesion 10, FIG. 5. As is known, the photopharmaceutical contained in the transparent hydrogel 50 is **toxic**, typically acidic, and its application to the skin of a patient can be at least somewhat discomforting or even painful. It has been discovered that by **reducing** the size of the hydrogel containing the photopharmaceutical a reduced but still biologically sufficient quantity of photopharmaceutical can be applied. . . the patient but with reduced discomfort. This also facilitates a photopharmaceutical profile that minimizes the application of the photopharmaceutical to **healthy tissue** at the dermal treatment site 25, FIG. 5, yet allows the controlled delivery of photoactivating light to the entire dermal treatment site 25. In application, and in practice of the **photodynamic therapy**, the trimmed hydrogel 54 resides within the cover 22 intermediate the transparent hydrogel 26A and the treatment site 25 as. . . same manner as the single layer of transparent hydrogel 26 in patch 20 of FIGS. 2 and 3 to apply **photodynamic therapy** to the dermal lesion 10.

ACCESSION NUMBER: 95:109983 USPATFULL  
TITLE: Combination controller and patch for the photodynamic therapy of dermal lesion  
INVENTOR(S): Meserol, Peter M., Montville, NJ, United States  
PATENT ASSIGNEE(S): Dusa Pharmaceuticals, Inc., Denville, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5474528		19951212
APPLICATION INFO.:	US 1994-215273		19940321 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Cohen, Lee S.		
ASSISTANT EXAMINER:	Nasser, Jr., Robert L.		
LEGAL REPRESENTATIVE:	Rhodes, Jr., R. Gale		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	705		

L3 ANSWER 1 OF 7 USPATFULL on STN  
 AN 2005:166041 USPATFULL  
 TI Topical aminolevulinic acid-**photodynamic** therapy for the treatment of acne vulgaris  
 IN Anderson, Richard Rox, Lexington, MA, UNITED STATES  
 PI US 2005143466 A1 20050630  
 AI US 2004-970922 A1 20041020 (10)  
 RLI Division of Ser. No. US 2001-929384, filed on 14 Aug 2001, PENDING  
 PRAI US 2000-225691P 20000816 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1203  
 INCL INCLM: 514/561.000  
 INCLS: 604/020.000  
 NCL NCLM: 514/561.000  
 NCLS: 604/020.000  
 IC [7]  
 ICM A61K031-195  
 ICS A61N001-30  
 IPCI A61K0031-195 [ICM,7]; A61K0031-185 [ICM,7,C\*]; A61N0001-30 [ICS,7]  
 IPCR A61K0041-00 [I,A]; A61K0041-00 [I,C\*]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 7 USPATFULL on STN  
 AN 2003:277223 USPATFULL  
 TI Method for **photodynamic** therapy and applicator for carrying out said therapy  
 IN Vorozhtsov, Georgy Nikolaevich, Moscow, RUSSIAN FEDERATION  
 Davydov, Anatoly Borisovich, Moscow, RUSSIAN FEDERATION  
 Kuzmin, Sergei Georgievich, Dolgoprudny Moskovski oblasti, RUSSIAN FEDERATION  
 Loschenov, Viktor Borisovich, Moscow, RUSSIAN FEDERATION  
 Luzhkov, Yuri Mikhailovich, Moscow, RUSSIAN FEDERATION  
 Lukyanets, Evgeny Antonovich, Moscow, RUSSIAN FEDERATION  
 Meerovich, Gennady Alexandrovich, Korolev Moskovskoi obl., RUSSIAN FEDERATION  
 Khromov, Gennady Lvovich, Moscow, RUSSIAN FEDERATION  
 PI US 2003195250 A1 20031016  
 AI US 2003-332476 A1 20030108 (10)  
 WO 2002-RU4 20020111  
 PRAI RU 2001-100688 20010112  
 DT Utility  
 FS APPLICATION  
 LN.CNT 389  
 INCL INCLM: 514/561.000  
 INCLS: 604/020.000  
 NCL NCLM: 514/561.000  
 NCLS: 604/020.000  
 IC [7]  
 ICM A61K031-195  
 ICS A61N001-30  
 IPCI A61K0031-195 [ICM,7]; A61K0031-185 [ICM,7,C\*]; A61N0001-30 [ICS,7]  
 IPCR A61B0005-00 [N,A]; A61B0005-00 [N,C\*]; A61N0005-06 [I,A]; A61N0005-06 [I,C\*]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 7 USPATFULL on STN  
 AN 2002:186172 USPATFULL  
 TI Topical aminolevulinic acid-**photodynamic** therapy for the treatment of acne vulgaris

IN Anderson, Richard Rox, Lexington, MA, UNITED STATES  
PI US 2002099094 A1 20020725  
US 6897238 B2 20050524  
AI US 2001-929384 A1 20010814 (9)  
PRAI US 2000-225691P 20000816 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1315  
INCL INCLM: 514/561.000  
INCLS: 604/020.000  
NCL NCLM: 514/563.000; 514/561.000  
NCLS: 424/059.000; 514/561.000; 514/814.000; 604/020.000  
IC [7]  
ICM A61K031-195  
ICS A61N001-30  
IPCI A61K0031-195 [ICM,7]; A61K0031-185 [ICM,7,C\*]; A61N0001-30  
[ICS,7]  
IPCI-2 A61K0031-195 [ICM,7]; A61K0031-185 [ICM,7,C\*]; A61K0007-42  
[ICS,7]  
IPCR A61K0041-00

(U.S. corporation)  
PI US 5127938 19920707  
AI US 1986-895529 19860811 (6)  
RLI Continuation of Ser. No. US 1985-754092, filed on 15 Jul 1985, now abandoned which is a continuation-in-part of Ser. No. US 1984-634932, filed on 27 Jul 1984, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1887  
INCL INCLM: 071/113.000  
INCLS: 071/065.000  
NCL NCLM: 504/319.000  
NCLS: 504/130.000; 504/245.000; 504/250.000; 504/283.000; 504/284.000  
IC [5]  
ICM A01N037-02  
IPCI A01N0037-02 [ICM,5]  
IPCR A01N0037-44 [I,A]; A01N0037-44 [I,C\*]; A01N0043-34 [I,C\*];  
A01N0043-40 [I,A]; A01N0043-42 [I,A]; A01N0043-90 [I,A];  
A01N0043-90 [I,C\*]  
EXF 071/65; 071/113  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s porphyrin/ab and l1  
L4 23 PORPHYRIN/AB AND L1

=> d 1-23

L4 ANSWER 1 OF 23 USPATFULL on STN  
AN 2006:104482 USPATFULL  
TI Liposomal formulations of hydrophobic photosensitizer for  
**photodynamic** therapy  
IN Albrecht, Volker, Jena, GERMANY, FEDERAL REPUBLIC OF  
Fahr, Alfred, Colbe/Marburg, GERMANY, FEDERAL REPUBLIC OF  
Scheglmann, Dietrich, Jena-Cospeda, GERMANY, FEDERAL REPUBLIC OF  
Grafe, Susanna, Jena, GERMANY, FEDERAL REPUBLIC OF  
Neuberger, Wolfgang, F.T. Labuan, MALAYSIA  
PA CeramOptec Industries, Inc. (non-U.S. corporation)  
PI US 2006088584 A1 20060427  
AI US 2005-298729 A1 20051209 (11)  
RLI Division of Ser. No. US 2003-648168, filed on 26 Aug 2003, PENDING  
DT Utility  
FS APPLICATION  
LN.CNT 474  
INCL INCLM: 424/450.000  
INCLS: 514/410.000; 514/023.000  
NCL NCLM: 424/450.000  
NCLS: 514/023.000; 514/410.000  
IC IPCI A61K0009-127 [I,A]; A61K0031-70 [I,A]; A61K0031-409 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 23 USPATFULL on STN  
AN 2005:260789 USPATFULL  
TI Substituted porphyrin and azaporphyrin derivatives and their use in  
**photodynamic** therapy, radioimaging and MRI diagnosis  
IN Robinson, Byron C., Santa Barbara, CA, UNITED STATES  
PA Miravant Pharmaceuticals, Inc. (U.S. corporation)  
PI US 2005226810 A1 20051013  
AI US 2005-59557 A1 20050217 (11)  
RLI Division of Ser. No. US 2002-159580, filed on 31 May 2002, GRANTED, Pat.  
No. US 6906050  
PRAI US 2001-295343P 20010531 (60)  
DT Utility  
FS APPLICATION

LN.CNT 3984  
INCL INCLM: 424/001.110  
INCLS: 514/185.000; 514/410.000; 514/063.000; 540/145.000; 534/016.000;  
424/009.362  
NCL NCLM: 424/001.110  
NCLS: 424/009.362; 514/063.000; 514/185.000; 514/410.000; 534/016.000;  
540/145.000  
IC [7]  
ICM A61K051-00  
ICS A61K031-695; C07F005-00; A61K031-555  
IPCI A61K0051-00 [ICM,7]; A61K0031-695 [ICS,7]; C07F0005-00 [ICS,7];  
A61K0031-555 [ICS,7]  
IPCR A61K0051-02 [I,C\*]; A61K0051-04 [I,A]; C07D0487-00 [I,C\*];  
C07D0487-22 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 23 USPATFULL on STN  
AN 2005:158970 USPATFULL  
TI Metallotetrapyrrolic photosensitizing agents for use in  
photodynamic therapy  
IN Robinson, Byron C., Santa Barbara, CA, UNITED STATES  
Leitch, Ian M., Goleta, CA, UNITED STATES  
Greene, Stephanie, Goleta, CA, UNITED STATES  
Rychnovsky, Steve, Santa Barbara, CA, UNITED STATES  
PA Miravant Pharmaceuticals, Inc. (U.S. corporation)  
PI US 2005137180 A1 20050623  
AI US 2004-965849 A1 20041018 (10)  
RLI Division of Ser. No. US 2002-159005, filed on 31 May 2002, GRANTED, Pat.  
No. US 6827926  
PRAI US 2001-295345P 20010531 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 6982  
INCL INCLM: 514/185.000  
INCLS: 540/145.000  
NCL NCLM: 514/185.000  
NCLS: 540/145.000  
IC [7]  
ICM A61K031-555  
ICS C07D487-22  
IPCI A61K0031-555 [ICM,7]; C07D0487-22 [ICS,7]; C07D0487-00 [ICS,7,C\*]  
IPCR A61K0041-00 [I,A]; A61K0041-00 [I,C\*]; A61K0049-00 [I,A];  
A61K0049-00 [I,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 23 USPATFULL on STN  
AN 2005:56198 USPATFULL  
TI Non-polar photosensitizer formulations for photodynamic  
therapy  
IN Albrecht, Volker, Jena, GERMANY, FEDERAL REPUBLIC OF  
Fahr, Alfred, Colbe, GERMANY, FEDERAL REPUBLIC OF  
Scheglmann, Dietrich, Jena, GERMANY, FEDERAL REPUBLIC OF  
Grafe, Susanna, Jena, GERMANY, FEDERAL REPUBLIC OF  
Neuberger, Wolfgang, F.T. Labuan, MALAYSIA  
PA CeramOptec Industries, Inc. (non-U.S. corporation)  
PI US 2005048109 A1 20050303  
AI US 2003-648168 A1 20030826 (10)  
DT Utility  
FS APPLICATION  
LN.CNT 520  
INCL INCLM: 424/450.000  
NCL NCLM: 424/450.000  
IC [7]  
ICM A61K009-127

IPCI A61K0009-127 [ICM,7]  
IPCR A61K0041-00 [I,A]; A61K0041-00 [I,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 23 USPATFULL on STN  
AN 2005:24011 USPATFULL  
TI Chlorins processing fused ring systems useful as photoselective compounds for **photodynamic** therapy  
IN Robinson, Byron C., Santa Barbara, CA, UNITED STATES  
Sengupta, Dipanjan, Goleta, CA, UNITED STATES  
Phadke, Avinash, Goleta, CA, UNITED STATES  
PA Miravant Pharmaceuticals, Inc. (U.S. corporation)  
PI US 2005020560 A1 20050127  
AI US 2004-922974 A1 20040823 (10)  
RLI Division of Ser. No. US 2000-538980, filed on 30 Mar 2000, GRANTED, Pat. No. US 6794505  
DT Utility  
FS APPLICATION  
LN.CNT 2590  
INCL INCLM: 514/185.000  
INCLS: 514/410.000; 540/001.000; 540/145.000  
NCL NCLM: 514/185.000  
NCLS: 514/410.000; 540/001.000; 540/145.000  
IC [7]  
ICM A61K031-555  
ICS C07D487-22  
IPCI A61K0031-555 [ICM,7]; C07D0487-22 [ICS,7]; C07D0487-00 [ICS,7,C\*]  
IPCR A61K0041-00 [I,A]; A61K0041-00 [I,C\*]; C07D0487-00 [I,C\*]; C07D0487-22 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 23 USPATFULL on STN  
AN 2004:327985 USPATFULL  
TI Porphyrin derivatives for **photodynamic** therapy  
IN Grierson, David, Versailles, FRANCE  
Maillard, Philippe, Saint-Cyr-L'Ecole, FRANCE  
Loock, Bernard, Villebon-Sur-Yvette, FRANCE  
Figueiredo, Telmo, La Madeleine, FRANCE  
Croisy, Alain, Cernay-La-Ville, FRANCE  
Carrez, Danielle, Marly-Le-Roi, FRANCE  
PI US 2004259810 A1 20041223  
AI US 2004-484529 A1 20040720 (10)  
WO 2002-IB3364 20020718  
PRAI EP 2001-401936 20010719  
DT Utility  
FS APPLICATION  
LN.CNT 1500  
INCL INCLM: 514/023.000  
INCLS: 536/017.400  
NCL NCLM: 514/023.000  
NCLS: 536/017.400  
IC [7]  
ICM A61K031-7052  
ICS C07H017-02  
IPCI A61K0031-7052 [ICM,7]; A61K0031-7042 [ICM,7,C\*]; C07H0017-02 [ICS,7]; C07H0017-00 [ICS,7,C\*]  
IPCR A61K0031-7042 [I,C\*]; A61K0031-7052 [I,A]; A61K0041-00 [I,A]; A61K0041-00 [I,C\*]; C07H0015-00 [I,C\*]; C07H0015-18 [I,A]; C07H0015-26 [I,A]; C07H0023-00 [I,A]; C07H0023-00 [I,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 23 USPATFULL on STN  
AN 2004:235584 USPATFULL  
TI Chlorins possessing fused ring systems useful as photoselective

compounds for **photodynamic** therapy

IN Robinson, Byron C., Santa Barbara, CA, United States  
 Sengupta, Dipanjan, Goleta, CA, United States  
 Phadke, Avinash, Goleta, CA, United States

PA Miravant Pharmaceuticals, Inc., Santa Barbara, CA, United States (U.S. corporation)

PI US 6794505 B1 20040921

AI US 2000-538980 20000330 (9)

DT Utility

FS GRANTED

LN.CNT 2273

INCL INCLM: 540/145.000  
 INCLS: 534/015.000; 534/016.000; 540/121.000

NCL NCLM: 540/145.000  
 NCLS: 534/015.000; 534/016.000; 540/121.000

IC [7]  
 ICM C07D487-22  
 IPCI C07D0487-22 [ICM,7]; C07D0487-00 [ICM,7,C\*]  
 IPCR A61K0041-00 [I,A]; A61K0041-00 [I,C\*]; C07D0487-00 [I,C\*];  
 C07D0487-22 [I,A]

EXF 540/145; 540/121; 534/15; 534/16

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 23 USPATFULL on STN

AN 2004:145059 USPATFULL

TI **Photodynamic** therapy for the treatment of non-melanoma skin cancer

IN Chan, Agnes H., Coquitlam, CANADA  
 Neyndorff, Herma C., Vancouver, CANADA

PI US 2004110731 A1 20040610

AI US 2002-310668 A1 20021204 (10)

DT Utility

FS APPLICATION

LN.CNT 471

INCL INCLM: 514/169.000

NCL NCLM: 514/169.000

IC [7]  
 ICM A61K031-56  
 IPCI A61K0031-56 [ICM,7]  
 IPCR A61K0041-00 [I,A]; A61K0041-00 [I,C\*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 23 USPATFULL on STN

AN 2003:312708 USPATFULL

TI Selective nuclear receptor-targeted systems for delivery of cytotoxins to cancer cells for targeted **photodynamic** therapy

IN Ray, Rahul, Wayland, MA, UNITED STATES  
 Mohr, Scott C., Wellesley, MA, UNITED STATES  
 Swamy, Narasimha, Providence, RI, UNITED STATES

PI US 2003220313 A1 20031127  
 US 7038041 B2 20060502

AI US 2002-257081 A1 20021107 (10)  
 WO 2001-US12196 20010412

DT Utility

FS APPLICATION

LN.CNT 620

INCL INCLM: 514/176.000  
 INCLS: 540/107.000

NCL NCLM: 540/145.000; 514/176.000  
 NCLS: 435/002.000; 534/015.000; 552/502.000; 540/107.000

IC [7]  
 ICM C07J043-00  
 ICS A61K031-58  
 IPCI C07J0043-00 [ICM,7]; A61K0031-58 [ICS,7]



IPCI-2 C07D0487-22 [I,A]; C07D0487-00 [I,C\*]; C07D0209-00 [I,A];  
A61K0031-555 [I,A]  
IPCR A61K0041-00 [I,A]; A61K0041-00 [I,C\*]; C07J0043-00 [I,A];  
C07J0043-00 [I,C\*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 23 USPATFULL on STN  
AN 2003:153402 USPATFULL  
TI Porphyrins with enhanced multi-photon absorption cross-sections for  
**photodynamic** therapy  
IN Nickel, Eric, Marietta, GA, UNITED STATES  
Spangler, Charles W., Livingston, MT, UNITED STATES  
Rebane, Aleksander, Bozeman, MT, UNITED STATES  
PI US 2003105070 A1 20030605  
US 6953570 B2 20051011  
AI US 2002-225303 A1 20020822 (10)  
PRAI US 2001-313815P 20010822 (60)  
US 2002-348393P 20020116 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1429  
INCL INCLM: 514/185.000  
INCLS: 514/410.000; 540/145.000  
NCL NCLM: 424/009.610; 514/185.000  
NCLS: 424/001.110; 424/001.650; 424/009.100; 424/009.362; 424/009.600;  
514/410.000; 540/145.000  
IC [7]  
ICM A61K031-555  
ICS A61K031-409; C07D487-22  
IPCI A61K0031-555 [ICM,7]; A61K0031-409 [ICS,7]; C07D0487-22 [ICS,7];  
C07D0487-00 [ICS,7,C\*]  
IPCI-2 A61B0010-00 [ICM,7]; A61B0005-00 [ICS,7]; A61B0008-00 [ICS,7]  
IPCR A61K0041-00 [I,A]; A61K0041-00 [I,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 23 USPATFULL on STN  
AN 2003:153401 USPATFULL  
TI Metallotetrapyrrolic photosensitizing agents for use in  
**photodynamic** therapy  
IN Robinson, Byron C., Santa Barbara, CA, UNITED STATES  
Leitch, Ian M., Goleta, CA, UNITED STATES  
Greene, Stephanie, Goleta, CA, UNITED STATES  
Rychnovsky, Steve, Santa Barbara, CA, UNITED STATES  
PI US 2003105069 A1 20030605  
US 6827926 B2 20041207  
AI US 2002-159005 A1 20020531 (10)  
PRAI US 2001-295345P 20010531 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 7007  
INCL INCLM: 514/185.000  
INCLS: 514/410.000; 604/020.000; 424/009.610  
NCL NCLM: 424/009.100; 514/185.000  
NCLS: 424/009.362; 424/009.420; 424/009.500; 424/009.610; 514/185.000;  
540/145.000; 514/410.000; 604/020.000  
IC [7]  
ICM A61K031-555  
ICS A61K031-409; A61K049-00; A61N001-30  
IPCI A61K0031-555 [ICM,7]; A61K0031-409 [ICS,7]; A61K0049-00 [ICS,7];  
A61N0001-30 [ICS,7]  
IPCI-2 A61K0031-409 [ICM,7]; A61K0049-00 [ICS,7]  
IPCR A61K0041-00 [I,A]; A61K0041-00 [I,C\*]; A61K0049-00 [I,A];  
A61K0049-00 [I,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 23 USPATFULL on STN  
 AN 2003:147005 USPATFULL  
 TI Substituted porphyrin and azaporphyrin derivatives and their use in  
**photodynamic** therapy, radioimaging and MRI diagnosis  
 IN Robinson, Byron C., Santa Barbara, CA, UNITED STATES  
 PI US 2003100752 A1 20030529  
 US 6906050 B2 20050614  
 AI US 2002-159580 A1 20020531 (10)  
 PRAI US 2001-295343P 20010531 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 4498  
 INCL INCLM: 540/145.000  
 INCLS: 534/702.000; 424/009.362; 514/150.000; 514/185.000; 604/020.000  
 NCL NCLM: 514/183.000; 540/145.000  
 NCLS: 514/063.000; 514/185.000; 514/189.000; 514/740.000; 540/121.000;  
 540/145.000; 424/009.362; 534/702.000; 604/020.000  
 IC [7]  
 ICM A61K049-00  
 ICS A61K031-655; A61K031-555; C07D487-22  
 IPCI A61K0049-00 [ICM,7]; A61K0031-655 [ICS,7]; A61K0031-555 [ICS,7];  
 C07D0487-22 [ICS,7]; C07D0487-00 [ICS,7,C\*]  
 IPCI-2 A61K0031-33 [ICM,7]; A61K0031-555 [ICS,7]; A61K0031-695 [ICS,7];  
 C07D0487-22 [ICS,7]; C07D0487-00 [ICS,7,C\*]  
 IPCR A61K0051-02 [I,C\*]; A61K0051-04 [I,A]; C07D0487-00 [I,C\*];  
 C07D0487-22 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 23 USPATFULL on STN  
 AN 2003:72009 USPATFULL  
 TI **Photodynamic** porphyrin antimicrobial agents  
 IN Bommer, Jerry C., Franklin, ID, UNITED STATES  
 Jori, Giulio, Padova, ITALY  
 PA Frontier Scientific, Inc. (U.S. corporation)  
 PI US 2003050296 A1 20030313  
 US 6573258 B2 20030603  
 AI US 2001-964286 A1 20010926 (9)  
 PRAI US 2000-235822P 20000927 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1526  
 INCL INCLM: 514/185.000  
 INCLS: 514/410.000; 540/145.000; 514/063.000  
 NCL NCLM: 514/185.000  
 NCLS: 514/333.000; 514/338.000; 514/410.000; 540/145.000; 514/063.000  
 IC [7]  
 ICM A61K031-695  
 ICS C07D487-22; A61K031-555  
 IPCI A61K0031-695 [ICM,7]; C07D0487-22 [ICS,7]; C07D0487-00  
 [ICS,7,C\*]; A61K0031-555 [ICS,7]  
 IPCI-2 A61K0031-409 [ICM,7]; C07D0487-22 [ICS,7]; C07D0487-00 [ICS,7,C\*]  
 IPCR A61K0031-409 [I,A]; A61K0031-409 [I,C\*]; A61K0031-4427 [I,C\*];  
 A61K0031-4439 [I,A]; A61K0041-00 [I,A]; A61K0041-00 [I,C\*];  
 C07D0487-00 [I,C\*]; C07D0487-22 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 23 USPATFULL on STN  
 AN 2003:31130 USPATFULL  
 TI Water-soluble porphyrin derivatives for **photodynamic** therapy,  
 their use and manufacture  
 IN Nifantiev, Nikolay E., Moscow, RUSSIAN FEDERATION  
 Yashunsky, Dmitri V., Moscow, RUSSIAN FEDERATION  
 PA CeramOptec Industries Inc. (non-U.S. corporation)

PI US 2003023081 A1 20030130  
 US 6777402 B2 20040817  
 AI US 2002-151764 A1 20020520 (10)  
 RLI Continuation-in-part of Ser. No. US 2001-871772, filed on 1 Jun 2001,  
 PENDING  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1541  
 INCL INCLM: 540/145.000  
 INCLS: 530/324.000; 536/017.400  
 NCL NCLM: 514/183.000; 540/145.000  
 NCLS: 514/410.000; 540/145.000; 530/324.000; 536/017.400  
 IC [7]  
 ICM C07D487-22  
 ICS C07H017-02  
 IPCI C07D0487-22 [ICM,7]; C07D0487-00 [ICM,7,C\*]; C07H0017-02 [ICS,7];  
 C07H0017-00 [ICS,7,C\*]  
 IPCI-2 C07D0487-22 [ICM,7]; C07D0487-00 [ICM,7,C\*]; A61K0031-409  
 [ICS,7]; A61P0035-00 [ICS,7]; A61P0033-00 [ICS,7]  
 IPCR A61K0041-00 [I,A]; A61K0041-00 [I,C\*]; C07D0487-00 [I,C\*];  
 C07D0487-22 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 23 USPATFULL on STN  
 AN 2002:251943 USPATFULL  
 TI Synthesis, and **photodynamic** therapy-mediated anti-cancer, and  
 other uses of chlorin e6-transferrin  
 IN Cavanaugh, Philip Gerard, Redford, MI, UNITED STATES  
 PI US 2002137901 A1 20020926  
 AI US 2002-46386 A1 20020116 (10)  
 PRAI US 2001-262674P 20010122 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 739  
 INCL INCLM: 530/400.000  
 NCL NCLM: 530/400.000  
 IC [7]  
 ICM C07K014-79  
 IPCI C07K0014-79 [ICM,7]; C07K0014-435 [ICM,7,C\*]  
 IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C\*]; A61K0041-00 [I,A];  
 A61K0041-00 [I,C\*]; C07K0014-435 [I,C\*]; C07K0014-79 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 23 USPATFULL on STN  
 AN 2002:88471 USPATFULL  
 TI Bacteriochlorins and bacteriopurpurins useful as photoselective  
 compounds for **photodynamic** therapy and a process for their  
 production  
 IN Robinson, Byron C., Santa Barbara, CA, United States  
 PA Miravant Pharmaceuticals, Inc., Santa Barbara, CA, United States (U.S.  
 corporation)  
 PI US 6376483 B1 20020423  
 AI US 1999-320731 19990527 (9)  
 DT Utility  
 FS GRANTED  
 LN.CNT 1194  
 INCL INCLM: 514/185.000  
 INCLS: 514/410.000; 534/015.000; 534/016.000; 534/010.000; 540/145.000;  
 424/009.610  
 NCL NCLM: 514/185.000  
 NCLS: 424/009.610; 514/410.000; 534/010.000; 534/015.000; 534/016.000;  
 540/145.000  
 IC [7]  
 ICM A61K031-409

ICS C07D487-22  
 IPCI A61K0031-409 [ICM,7]; C07D0487-22 [ICS,7]; C07D0487-00 [ICS,7,C\*]  
 IPCR A61K0041-00 [I,A]; A61K0041-00 [I,C\*]; C07D0487-00 [I,C\*];  
 C07D0487-22 [I,A]  
 EXF 540/145; 514/185; 514/410; 534/10; 534/15; 534/16; 424/9.61  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 23 USPATFULL on STN  
 AN 2001:93500 USPATFULL  
 TI Use of **photodynamic** therapy for prevention of secondary  
 cataracts  
 IN Meadows, Howard E., Vancouver, Canada  
 Wenkster, Danielle, Lions Bay, Canada  
 Mallek, David R., Vancouver, Canada  
 Bussanich, Marcello Nick, Vancouver, Canada  
 Richter, Anna M., Vancouver, Canada  
 Levy, Julia G., Vancouver, Canada  
 Hariton, Claude A. A., Brinckhein, France  
 Huber, Gustav, Rafz, Switzerland  
 Rootman, Jack, Vancouver, Canada  
 PA QLT, Inc., Canada (non-U.S. corporation)  
 The University of British Columbia, Canada (non-U.S. corporation)  
 Ciba Vision Ophthalmics, Switzerland (non-U.S. corporation)  
 PI US 6248734 B1 20010619  
 AI US 2000-536291 20000327 (9)  
 RLI Division of Ser. No. US 1996-762854, filed on 10 Dec 1996, now patented,  
 Pat. No. US 6043237  
 DT Utility  
 FS GRANTED  
 LN.CNT 1126  
 INCL INCLM: 514/185.000  
 INCLS: 514/054.000; 514/055.000; 514/912.000  
 NCL NCLM: 514/185.000  
 NCLS: 514/054.000; 514/055.000; 514/912.000  
 IC [7]  
 ICM A01N055-02  
 IPCI A01N0055-02 [ICM,7]; A01N0055-00 [ICM,7,C\*]  
 IPCR A61K0041-00 [I,A]; A61K0041-00 [I,C\*]  
 EXF 514/185; 514/912; 514/54; 514/55  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 23 USPATFULL on STN  
 AN 2000:142407 USPATFULL  
 TI 3-, 8-substituted deuteroporphyrin derivatives, pharmaceutical agents  
 that contain the latter, process for their production and their use in  
**photodynamic** therapy and MRI diagnosis  
 IN Platzeck, Johannes, Berlin, Germany, Federal Republic of  
 Niedballa, Ulrich, Berlin, Germany, Federal Republic of  
 Raduechel, Bernd, Berlin, Germany, Federal Republic of  
 Ebert, Wolfgang, Mahlow, Germany, Federal Republic of  
 Weinmann, Hanns-Joachim, Berlin, Germany, Federal Republic of  
 Frenzel, Thomas, Berlin, Germany, Federal Republic of  
 PA Schering Aktiengesellschaft, Berlin, Germany, Federal Republic of  
 (non-U.S. corporation)  
 PI US 6136841 20001024  
 AI US 1999-323996 19990602 (9)  
 PRAI DE 1998-19825512 19980602  
 US 1998-110697P 19981203 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 1051  
 INCL INCLM: 514/410.000  
 INCLS: 540/145.000; 424/009.300; 424/009.362; 534/014.000; 534/015.000;  
 534/016.000; 534/010.000; 534/009.000; 534/008.000

NCL NCLM: 514/410.000  
NCLS: 424/009.300; 424/009.362; 514/064.000; 534/010.000; 534/014.000;  
534/015.000; 534/016.000; 540/145.000  
IC [7]  
ICM A61K049-00  
ICS C07D487-22  
IPCI A61K0049-00 [ICM,7]; C07D0487-22 [ICS,7]; C07D0487-00 [ICS,7,C\*]  
IPCR A61K0041-00 [I,A]; A61K0041-00 [I,C\*]; A61K0049-06 [I,C\*];  
A61K0049-08 [I,A]; C07D0487-00 [I,C\*]; C07D0487-22 [I,A]  
EXF 540/145; 540/474; 514/410; 424/9.362; 424/9.3; 534/10-16  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 19 OF 23 USPATFULL on STN  
AN 2000:117702 USPATFULL  
TI Porphyrin derivatives, pharmaceutical agents that contain the latter,  
and their use in **photodynamic** therapy and MRI diagnosis  
IN Platzek, Johannes, Berlin, Germany, Federal Republic of  
Niedballa, Ulrich, Berlin, Germany, Federal Republic of  
Raduechel, Bernd, Berlin, Germany, Federal Republic of  
Weinmann, Hanns-Joachim, Berlin, Germany, Federal Republic of  
Frenzel, Thomas, Berlin, Germany, Federal Republic of  
Ebert, Wolfgang, Mahlow, Germany, Federal Republic of  
PA Schering Aktiengesellschaft, Berlin, Germany, Federal Republic of  
(non-U.S. corporation)  
PI US 6114321 20000905  
AI US 1999-346891 19990702 (9)  
PRAI DE 1998-19831217 19980703  
US 1998-110696P 19981203 (60)  
DT Utility  
FS Granted  
LN.CNT 1303  
INCL INCLM: 514/185.000  
INCLS: 514/183.000; 514/184.000; 514/186.000; 540/145.000; 540/472.000;  
540/474.000; 540/465.000; 424/009.362; 534/015.000  
NCL NCLM: 514/185.000  
NCLS: 424/009.362; 514/183.000; 514/184.000; 514/186.000; 534/015.000;  
540/145.000; 540/465.000; 540/472.000; 540/474.000  
IC [7]  
ICM C07D487-22  
ICS A61K031-40  
IPCI C07D0487-22 [ICM,7]; C07D0487-00 [ICM,7,C\*]; A61K0031-40 [ICS,7]  
IPCR A61K0031-40 [I,A]; A61K0031-40 [I,C\*]; C07D0487-00 [I,C\*];  
C07D0487-22 [I,A]  
EXF 514/185; 514/183; 514/184; 514/186; 540/145; 540/474; 424/9.362; 534/15  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 20 OF 23 USPATFULL on STN  
AN 2000:37793 USPATFULL  
TI Use of **photodynamic** therapy for prevention of secondary  
cataracts  
IN Meadows, Howard E., Vancouver, Canada  
Wenkstern, Danielle, Lions Bay, Canada  
Mallek, David R., Vancouver, Canada  
Bussanich, Marcello Nick, Vancouver, Canada  
Richter, Anna M., Vancouver, Canada  
Levy, Julia G., Vancouver, Canada  
Hariton, Claude A. A., Brinckhein, France  
Huber, Gustav, Zurich, Switzerland  
Rootman, Jack, Vancouver, Canada  
PA QLT PhotoTherapeutics, Inc., Canada (non-U.S. corporation)  
The University of the British of Columbia, Canada (non-U.S. corporation)  
Ciba Vision Ophthalmics, Switzerland (non-U.S. corporation)  
PI US 6043237 20000328  
AI US 1996-762854 19961210 (8)

DT Utility  
FS Granted  
LN.CNT 1146  
INCL INCLM: 514/185.000  
INCLS: 514/912.000  
NCL NCLM: 514/185.000  
NCLS: 514/912.000  
IC [7]  
ICM A61K031-555  
IPCI A61K0031-555 [ICM,7]  
IPCR A61K0041-00 [I,A]; A61K0041-00 [I,C\*]  
EXF 514/185; 514/912  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 21 OF 23 USPATFULL on STN  
AN 93:42055 USPATFULL  
TI Benzoporphyrin derivatives for photodynamic therapy  
IN Allison, Beth A., Vancouver, Canada  
Richter, Anna M., Vancouver, Canada  
Pritchard, P. Haydn, Vancouver, Canada  
Levy, Julia G., Vancouver, Canada  
PA University of British Columbia, British Columbia, Canada (non-U.S. corporation)  
PI US 5214036 19930525  
AI US 1990-491674 19900308 (7)  
DT Utility  
FS Granted  
LN.CNT 951  
INCL INCLM: 514/185.000  
INCLS: 514/410.000; 530/359.000  
NCL NCLM: 514/185.000  
NCLS: 514/410.000; 530/359.000  
IC [5]  
ICM A61K031-40  
ICS A61K047-42  
IPCI A61K0031-40 [ICM,5]; A61K0047-42 [ICS,5]  
IPCR A61K0031-40 [I,A]; A61K0031-40 [I,C\*]; A61K0041-00 [I,A];  
A61K0041-00 [I,C\*]  
EXF 514/21.185; 514/410; 424/450; 530/359  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 22 OF 23 USPATFULL on STN  
AN 91:92651 USPATFULL  
TI Derivatives of porphyrin useful in photodynamic therapy  
IN Chang, Chi-Kwong, Brighton, MI, United States  
Wu, Weishih, East Lansing, MI, United States  
PA Board of Trustees, a Constitutional Corporation Operating Michigan State University, East Lansing, MI, United States (U.S. corporation)  
PI US 5064952 19911112  
AI US 1990-464860 19900116 (7)  
DT Utility  
FS Granted  
LN.CNT 619  
INCL INCLM: 540/145.000  
NCL NCLM: 540/145.000  
IC [5]  
ICM C07D487-22  
ICS A61K031-40  
IPCI C07D0487-22 [ICM,5]; C07D0487-00 [ICM,5,C\*]; A61K0031-40 [ICS,5]  
IPCR A61K0041-00 [I,A]; A61K0041-00 [I,C\*]; A61K0049-00 [I,A];  
A61K0049-00 [I,C\*]; C07D0487-00 [I,C\*]; C07D0487-22 [I,A]  
EXF 514/185; 514/410; 540/145  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 23 OF 23 USPATFULL on STN  
AN 91:79975 USPATFULL  
TI Compositions for **photodynamic** therapy  
IN Liu, Daniel, Vancouver, Canada  
PA Quadra Logic Technologies Inc., Vancouver, Canada (non-U.S. corporation)  
PI US 5053423 19911001  
AI US 1990-498042 19900322 (7)  
DT Utility  
FS Granted  
LN.CNT 968  
INCL INCLM: 514/410.000  
INCLS: 514/002.000; 540/145.000  
NCL NCLM: 514/410.000  
NCLS: 514/002.000; 540/145.000  
IC [5]  
ICM A61K031-40  
ICS C07D487-22  
IPCI A61K0031-40 [ICM,5]; C07D0487-22 [ICS,5]; C07D0487-00 [ICS,5,C\*]  
IPCR A61K0041-00 [I,A]; A61K0041-00 [I,C\*]; A61K0047-48 [I,A];  
A61K0047-48 [I,C\*]  
EXF 514/2; 514/410; 540/145  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.